Components of equity [axis]
Number of ordinary shares [Member]
Accumulated other comprehensive income [Member]
Other reserves [Member]
Additional paid in capital [Member]
Accumulated deficit [Member]
Joint ventures [axis]
D.N.A. and Oramed [Member]
D.N.A. Biomedical Solutions Ltd. [Member]
Borrowings by name [axis]
2012 Convertible Loan [Member]
2012 Convertible Loan, 2016 Convertible Loan [Member]
2016 Convertible Loan [Member]
Ranges of exercise prices for outstanding share options [axis]
Exercise Price One [Member]
Classes of share capital [axis]
Series B preferred shares [Member]
Separate management entities [axis]
Investors [Member]
Broker dealer [Member]
Preferred Shares Series B- 1 [Member]
Oramed [Member]
Series A preferred shares [Member]
IPO [Member]
Warrants [Member]
Ordinary shares [member]
Series B-1 preferred shares [Member]
Warrants to series A preferred shares [Member]
Warrants to series B preferred shares [Member]
Warrants to series B-1 preferred shares [Member]
Underwriters [Member]
Types of share-based payment arrangements [axis]
Certain Consultant [Member]
Categories of related parties [axis]
Amgen Inc [Member]
Non-adjusting events after reporting period [axis]
Classes of financial instruments [Axis]
Financial Instruments [Member]
Classes of financial liabilities [axis]
Financial liabilities at fair value through profit or loss [Member]
Financial liabilities at amortized cost [Member]
Exercise Price Two [Member]
Exercise Price Three [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
Exercise Price Six [Member]
Exercise Price Seven [Member]
Exercise Price Eight [Member]
Exercise Price Nine [Member]
Exercise Price Ten [Member]
Exercise Price Eleven [Member]
Placement Agency agreement with GP Numenkari Inc [Member]
Broker Warrants type 1 [Member]
Broker Warrants type 2 [Member]
New US-based CFO [Member]
Non-executive director [Member]
Certain employees [Member]
CMO [Member]
New CEO [Member]
D.N.A. Placement [Member]
Subscription agreements with select group of accredited investors for private placement [Member]
Classes of assets [axis]
Facility [Member]
Vehicles [Member]
Maturity [axis]
Less than 1 year [Member]
1-3 years [Member]
Buildings [Member]
Classes of property, plant and equipment [axis]
Office furniture [Member]
Computers equipment [Member]
Range [axis]
Bottom of range [Member]
Top of range [Member]
Lab equipment [Member]
Leasehold improvements [Member]
Exercise Price Twelve [Member]
Options granted to services providers [Member]
Share-based Compensation Expense [member]
Initially applied IFRS [Axis]
Initial Application of IFRS 16 [Member]
Chief Executive officer [Member]
ATM Program [Member]
2015 Convertible Loan [Member]
Under Company Plan [Member]
Certain Employees [Member]
Certain Service Provider [Member]
Certain Executive Officers [Member]
Former CEO [Member]
Investor Relations Services Agreement [Member]
Consultant [Member]
Restricted Share Units [Member]
Vest In Three Equal Installments [Member]
Amendment To Business Development Services Agreement [Member]
Executive officers and former Executive officer [Member]
2012 Convertible Loan, preferred shares and warrants [Member]
Leases [Member]
Investor Warrant [Member]
Service Provider [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Entity Interactive Data Current
Is Entity's Reporting Status Current?
Entity Incorporation, State or Country Code
Entity File Number
Document Annual Report
Document Transition Report
Document Shell Company Report
Entity Filer Category
Entity Shell Company
Entity Emerging Growth Company
Entity Transition Period
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of financial position [abstract]
Assets
CURRENT ASSETS:
Cash and cash equivalents
Accounts receivable
Other current assets
TOTAL CURRENT ASSETS
NON-CURRENT ASSETS:
Property and equipment
Right of use assets
Intangible assets
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
Liabilities and shareholders' equity
CURRENT LIABILITIES:
Accounts payable:
Trade
Other
Current maturities of lease liabilities
Warrants to purchase ordinary shares
Contract liabilities
TOTAL CURRENT LIABILITIES
NON-CURRENT LIABILITIES:
Lease liabilities
Severance pay obligations, net
TOTAL NON-CURRENT LIABILITIES
TOTAL LIABILITIES
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2020 and December 31, 2019, 140,010,000 shares; issued and outstanding: as of December 31, 2020, and December 31, 2019 21,057,922 and 17,864,684 shares, respectively
Accumulated other comprehensive income
Other reserves
Additional paid in capital
Accumulated deficit
TOTAL SHAREHOLDERS' EQUITY
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
Ordinary Shares, par value
Ordinary Shares, Authorized
Ordinary Shares, Issued
Ordinary Shares, Outstanding
Profit or loss [abstract]
REVENUE
COST OF REVENUE
RESEARCH AND DEVELOPMENT EXPENSES, NET
GENERAL AND ADMINISTRATIVE EXPENSES
OPERATING LOSS
FINANCIAL INCOME:
Income from change in fair value of financial liabilities at fair value through profit or loss, net
Other financial expenses (income), net
FINANCIAL INCOME, net
LOSS BEFORE TAXES
TAXES ON INCOME
NET COMPREHENSIVE LOSS FOR THE YEAR
LOSS PER ORDINARY SHARE:
Basic
Diluted
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES:
Basic
Diluted
Statement of changes in equity [table]
Statement of changes in equity [line items]
BALANCE
BALANCE, shares
CHANGES DURING THE YEAR ENDED DECEMBER 31
Issuance of shares
Issuance of shares, shares
Net loss for the year
Issuance of shares and warrants, net
Issuance of shares and warrants, net, shares
Conversion of Preferred shares into Ordinary shares
Conversion of Preferred shares into Ordinary shares, shares
Conversion of convertible loan into Ordinary shares
Conversion of convertible loan into Ordinary shares, shares
Classification of Warrants to purchase preferred shares and shares into Warrants to purchase ordinary shares
Reclassification due to share-based compensation expired
Exercise of options to ordinary shares
Exercise of options to ordinary shares, shares
Issuance of shares due to exercise of right to purchase ordinary shares
Issuance of shares due to exercise of right to purchase ordinary shares, shares
Issuance of shares and warrant due to a private placement, net of issuance costs
Issuance of shares and warrant due to a private placement, net of issuance costs, shares
Issuance of shares due to the ATM program, net of issuance costs
Issuance of shares due to the ATM program, net of issuance costs, shares
Expiration of options and warrants
Vested restricted share units
Vested restricted share units, shares
Reclassification due to share-based compensation and warrants expired
Share-based compensation
Reclassification of capital contribution from controlling shareholder
BALANCE
BALANCE, shares
Statement of cash flows [abstract]
CASH FLOWS USED IN OPERATING ACTIVITIES:
Adjustments required to reflect net cash used in operating activities (see appendix A)
Net cash used in operating activities
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
Restricted deposits
Short-term bank deposits
Purchase of property and equipment
Net cash provided by (used in) investing activities
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
Principle element of lease payments
Issuance of ordinary shares and warrants, net of issuance costs
Proceeds from exercise of warrants
Proceeds from exercise of options
Net cash provided by financing activities
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR
CASH AND CASH EQUIVALENTS AT END OF THE YEAR
Adjustments required to reflect net cash used in operating activities:
Depreciation
Change in fair value of financial liabilities at fair value through profit or loss
Issuance costs
Financial expenses, net
Net changes in severance pay obligation
Total adjustments
Changes in working capital:
Decrease (increase) in accounts receivable
Decrease (increase) in other current assets
Increase (decrease) in accounts payable:
Trade
Other
Increase (decrease) in contract liabilities
Changes in working capital
Cash used for operating activities:
Interest received
Interest paid
Cash used for operating activities
Supplementary information on investing and financing activities not involving cash flows:
Conversion of preferred shares into ordinary shares
Conversion of convertible loan into ordinary shares
Right of use assets obtained in exchange for new operating lease liabilities
Vested restricted shares units
Disclosure of general information [abstract]
GENERAL INFORMATION
Disclosure of summary of significant accounting policies [abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Disclosure of critical accounting estimates and judgements [abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS
Disclosure of detailed information about intangible assets [abstract]
INTANGIBLE ASSETS
Disclosure of detailed information about borrowings [abstract]
CONVERTIBLE LOANS
Disclosure of preferred shares and warrants to prefered shares [abstract]
PREFERRED SHARES AND WARRANTS TO PREFERED SHARES
Disclosure of contingent liabilities [abstract]
COMMITMENTS
Presentation of leases for lessee [abstract]
LEASES
Disclosure of classes of share capital [abstract]
SHARE CAPITAL
Major components of tax expense (income) [abstract]
TAXES ON INCOME
Receivables from contracts with customers [abstract]
REVENUE FROM COLLABORATION AND LICENSE AGREEMENT
Disclosure of supplementary financial information [abstract]
SUPPLEMENTARY FINANCIAL INFORMATION
Basic and diluted earnings per share [abstract]
BASIC AND DILUTED LOSS PER SHARE
Disclosure of transactions between related parties [abstract]
RELATED PARTIES - TRANSACTIONS AND BALANCES
Disclosure of non-adjusting events after reporting period [abstract]
SUBSEQUENT EVENTS
Summary Of Significant Accounting Policies
Basis of preparation of the financial statements
Functional and presentation currency
Basis of consolidation
Cash and cash equivalents
Short-term bank deposits
Restricted deposits
Property and equipment
Intangible assets
Impairment of non-financial assets
Adjustments recognized on adoption of IFRS 16
Leases
Segment reporting
Financial instruments
Warrants
Share capital
Deferred income tax
Share-based payments
Revenue recognition
Cost of revenues
Government grants
Loss per ordinary share
Recently Issued Accounting Pronouncements
Standards and interpretations to existing standards that are not yet in effect but have been early adopted by the Company
Newly issued and recently adopted Accounting Pronouncements
New standards, amendments to standards or interpretations
Schedule of Estimated Useful Lives of Assets
Schedule of Classification of Financial Instruments by Groups
Schedule of Assumptions
Schedule of Convertible Components
Schedule of Convertible Loans
Preferred Shares And Warrants To Prefered Shares
Schedule of Movements in Three Components
Schedule of Valuations of Fair Value of Instruments
Schedule of Composition of Right-of-Use Assets
Schedule of Summarize Contractual Obligations
Schedule of Leases
Schedule of Composition of Ordinary Shares
Schedule of Weighted Average Assumptions
Schedule of Changes in Number of Options and Weighted Average Exercise Prices
Schedule of Information about Exercise Price and Remaining Contractual Life of Outstanding Options
Schedule of Revenues
Supplementary Financial Information
Schedule of Other Current Assets
Schedule of Accounts Payable Other
Schedule of Basic and Diluted Loss Per Share
Schedule of Transactions with Related Parties
Schedule of Balances with Related Parties
Statement Table [Table]
Statement Line Items [Line Items]
Accumulated losses
Number of shares issued
Net proceeds from issuing shares
Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services
Revenue from contract with customer
Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services
Disclosure of detailed information about property, plant and equipment [table]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives
Disclosure of detailed information about financial instruments [table]
Disclosure of detailed information about financial instruments [line items]
Categories of financial assets [axis]
Trade and other payable
Convertible loans (Level 3)
Preferred shares (Level 3)
Warrants to purchase ordinary shares (Level 1)
Warrants to purchase ordinary shares (Level 3)
Liability to issue preferred shares and warrants
Lease liabilities
Financial liabilities
Classes of financial instruments [axis]
Price per share
Volatility
Expected term
Risk free interest rate
Expected dividend
Disclosure of detailed information about intangible assets [table]
Disclosure of detailed information about intangible assets [line items]
Percentage of ordinary shares
Amount invested in joint venture
Percentage of royalties to be paid
Percentage of weighted average cost of capital
Commencement of sales years
Percentage of probability of reaching sales
Disclosure of detailed information about borrowings [table]
Disclosure of detailed information about borrowings [line items]
Borrowings
Interest rate
Maturity
Conversion price per share
Convertible loan converted into ordinary shares
Number of ordinary shares exchanged
Number of stock merged
Discount to the applicable price per share in the triggering event
Description of automatically converted loan to shares
Exercisable period of warrants
Amount payable in shares
Convertible loan and accrued interest converted into series B-1 preferred shares
Exercise price of warrants
Percentage of warrants to purchase additional shares on conversion
Finance expenses
Deposit amount at trustee
Repayments of borrowings
Disclosure of classes of share capital [table]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased after share split
Proceeds from issue of preferred shares
Preferred shares, price per share
Warrants issued to purchase preferred shares
Warrants issued to purchase shares after share split
Fair value of preferred shares
Fair value of warrants
Percentage of discount applicable to price per share
Number of warrants converted into additional warrants to purchase ordinary shares
Total consideration net of issuance costs
Additional issuance costs
Shares issued in conversion of debt
Number of preferred shares converted to ordinary shares following closing of IPO
Shares issued in conversion of debt, value
Shares issued in conversion of debt, price per share
Options granted to purchase ordinary shares
Interest rate on preferred shares
Conversion into ordinary shares
Warrant term
Effective price per share
Reclassification from other reserves to additional paid in capital
Exceeds sales price per share
Percentage of per unit price
Options exercised
Value of options exercised
Percentage of royalty payable on sales of products developed during first three years
Percentage of royalty payable on sales of products developed during subsequent three years
Percentage of royalty payable on sales of products developed during commencing of seventh year
Percentage of royalty payable on grants received by company
Royalty amount payable
Percentage to be paid for each payment received
Amount paid to government of israel
Disclosure of quantitative information about right-of-use assets [table]
Disclosure of quantitative information about right-of-use assets [line items]
Annual lease consideration total amount
Lease expiration date
Bank guarantees
Borrowings rate
InitiallyAppliedIFRSAxis [Axis]
Total right-of-use asset
Disclosure of maturity analysis of operating lease payments [table]
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles
Depreciation expense:
Financial expense
Cash paid for amounts included in the measurement of lease liabilities
Right of use assets obtained in exchange for expanded period of operating lease liabilities
Stock split
Increase of ordinary shares remain available for future grants
Warrants issued to purchase shares
Warrants converted into ordinary shares
Proceeds from issuance of ordinary shares, net
Proceeds from issuance of ordinary shares, gross
Stock issuance costs
Underwriters fee
Other issuance costs
Adjusted exercise price of warrants
Public offering price per unit
Number of ordinary shares that can be purchased through each tradeable warrant
Ordinary shares remain available for future grants
Proceeds from private placement
Share issue price per share
Percentage of cash fees of total proceeds
Percentage of number of shares issued to subscribers
Percentage of aggregate purchase price paid in cash by purchasers equal to per month
Par value per share
Warrants granted to purchase ordinary shares
Exercise price
Options vesting description
Fair value of options
Remaining unrecognized compensation expense
Transaction costs
Capital stock price per share
Reserved ordinary shares
Number of options exrercised to ordinary shares
Transfer from other reserves to additional paid in capital
Weighted average price
Number of options forfieted
General and administrative expenses reversal
Service monthly fees
Number of shares vested
Authorized
Issued
Ordinary share price
Exercise price
Dividend yield
Expected volatility
Risk-free interest rate
Expected life - in years
Number of options
Outstanding at beginning of year
Expired
Forfeited
Exercised
Granted
Outstanding at end of year
Exercisable at end of year
Weighted average exercise price
Outstanding at beginning of year
Expired
Forfeited
Exercised
Granted
Outstanding at end of year
Exercisable at end of year
Intrinsic value
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding at end of year
Exercise price
Weighted average of remaining contractual life
Israel corporate tax rates
Carryforward losses
Income tax rate in United states
Disclosure of disaggregation of revenue from contracts with customers [table]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Milestone payments
Non-refundable and non-creditable initial technology access fee payment
Amount to be paid for preclinical services
Contract Liabilities
Amount of performance obligations
Supplementary Financial Information Schedule Of Other Current Assets
Other current assets:
Prepaid expenses
Restricted deposits
Other
Other current assets
Supplementary Financial Information Schedule Of Accounts Payable Other
Accounts payable - other:
Employees and employees related
Provision for vacation
Accrued expenses and other
Accounts payable - other
Number of ordinary shares related to the outstanding options excluded from the calculation of diluted loss per share
Loss attributable to equity holders of the Company
Income from change in fair value of financial liabilities at fair value
Loss used for the computation of diluted loss per share
Weighted average number of ordinary shares used in the computation of basic loss per share
Add: Weighted average number of additional shares issuable upon the assumed conversion/exercise of preferred shares and warrants to issue preferred shares and shares
Weighted average number of ordinary shares used in the computation of diluted loss per share
Basic loss per ordinary share
Diluted loss per ordinary share
Key management compensation:
Labor cost and related expenses
Share-based compensation
Directors fee and services
Others
Key management compensation
Key management:
Payables and accrued expenses
Severance pay obligations
Provision for vacation
Directors fee and services
Disclosure of non-adjusting events after reporting period [table]
Disclosure of non-adjusting events after reporting period [line items]
Options granted/exercised to purchase ordinary shares
Proceeds from ordinary shares issued
Weighted average share price
Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services.
Additional Centillion preferred share purchase agreement [Member]
Additional share purchase agreements with HFN Trust [Member]
Additional share purchase agreements with WFI [Member]
Additional share purchase agreements with White Car [Member]
Adjusted exercise price of warrants.
Adjustments for changes in working capital to reconcile profit (loss) to net cash flow from (used in) operating activities.
Adjustments for increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.
Adjustments for issuance costs related to ordinary shares, preferred shares, convertible loans and warrants.
Adjustments for net changes in severance pay to reconcile profit (loss) to net cash flow from (used in) operating activities.
Amgen Agreement [Member]
Amgen Inc [Member]
Amount paid to government of israel.
Amount payable in shares.
Bank guarantees as of balance sheet date.
The description of the entity's accounting policy for the basis of consolidation.
Broker dealer [Member]
Broker Warrants type 1 and 2 [Member]
Broker Warrants type 1 [Member]
Broker Warrants type 2 [Member]
Capital stock price per share.
Amount of carryforward losses.
The cash inflow (outflow) due to a decrease (increase) in restricted deposits.
Centillion preferred share purchase agreement [Member]
Certain Consultant [Member]
Certain Director [Member]
Certain Employees [Member]
Certain Service Providers and Executive Officers [Member]
Certain Service Providers [Member]
CEO, COO and CFO [Member]
Chief Marketing Officer [Member]
Chief Medical Officer [Member]
CMO [Member]
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Consultant [Member]
Conversion into ordinary shares.
Conversion of Preferred shares into Ordinary shares.
Conversion of Preferred shares into Ordinary shares, shares.
Conversion of warrants to purchase preferred shares and shares into warrants to purchase ordinary shares and shares.
Debt conversion price per share.
2012 Convertible Loan, 2016 Convertible Loan, preferred shares and warrants [Member]
2012 Convertible Loan [Member]
2015 Convertible Loan [Member]
2016 Convertible Loan [Member]
Convertible loan and accrued interest converted into series B-1 preferred shares.
Convertible loan converted into ordinary shares.
D.N.A. Biomedical Solutions Ltd. [Member]
D.N.A [Member]
D.N.A. Placement [Member]
D.N.A. and Oramed [Member]
Deposit amount at trustee.
The description of the entity's accounting policy for adjustments recognized on adoption of IFRS 16.
The description of the entity's accounting policy for basis of preparation of the financial statements.
The description of the entity's accounting policy for changes in accounting policies and disclosures.
The description of the entity's accounting policy for cost of revenues.
The description of the entity's accounting policy for Standards and interpretations to existing standards that are not yet in effect but have been early adopted by the Company.
The description of the entity's accounting policy for Newly issued and recently adopted Accounting Pronouncements.
The description of the entity's accounting policy for short-term bank deposits.
Description of automatically converted loan to shares.
Description of commencement of sales years.
Exercisable period of warrants.
The expected volatility of the convertible loans used to calculate the fair value of the loans. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period.
The amounts payable resulting from directors fee and services related party transactions.
The disclosure of detailed information about basic and diluted loss per share.
The disclosure of detailed information about convertible components.
The disclosure of detailed information about estimated useful lives of assets.
The disclosure of detailed information about movements in three components.
The disclosure of detailed information about valuations of fair value of instruments.
The disclosure of detailed information about assumptions of financial instruments.
The entire disclosure for preferred shares and warrants to prefered shares.
The entire disclosure for supplementary financial information.
Dr. Eric Lang [Member]
Effective price per share.
Dr. Eric Lang [Member]
Exceeds sales price per share.
Executive officers and former Executive officer [Member]
Exercise Price Eight [Member]
Exercise Price Eleven [Member]
Exercise Price Five [Member]
Exercise Price Four [Member]
Exercise Price Nine [Member]
Exercise price of warrants.
Exercise Price One [Member]
Exercise Price Seven [Member]
Exercise Price Six [Member]
Exercise Price Ten [Member]
Exercise Price Three [Member]
Exercise Price Twelve [Member]
Exercise Price Two [Member]
Expected dividend.
Expected term.
Facility [Member]
Fair value of preferred shares.
Fair value of warrants.
The amount of income expense associated with interest and other financing activities of the entity.
Financial Instruments [Member]
HFN Trust [Member]
Customs elements.
Customs elements.
Income from change in fair value of financial liabilities at fair value.
Income from change in fair value of financial liabilities at fair value through profit or loss.
Income tax rate.
The increase (decrease) in number of shares resulting from the conversion of convertible instruments.
The increase (decrease) in number of shares resulting from the exercise of warrants.
The increase (decrease) in equity resulting from share-based payment transactions of warrants.
Increase of ordinary shares remain available for future grants.
Initial Application Of Ifrs 16 [Member]
IPO [Member]
Initially Applied IFRS [Axis]
Interest rate on preferred shares.
Investors, few related parties [Member]
Investors [Member]
Issuance of shares and warrant due to a private placement, net of issuance costs.
Number of issuance of shares and warrant due to a private placement, net of issuance costs.
Issuance of shares and warrants, net.
Issuance of shares and warrants, net, shares.
Issuance of shares due to exercise of right to purchase ordinary shares.
Number of issuance of shares due to exercise of right to purchase ordinary shares.
The increase in number of shares equity through the issue of equity instruments.
Directors fee and services to related parties.
Lab equipment [Member]
Lease expiration date.
The non-current portion of liability to issue preferred shares and warrants.
Liability to issue preferred shares and warrants [Member]
Mr. Luke Beshar [Member]
The amount of future minimum lease payments payable under non-cancellable operating leases. Minimum lease payments are payments over the lease term that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with: (a) for a lessee, any amounts guaranteed by the lessee or by a party related to the lessee; or (b) for a lessor, any residual value guaranteed to the lessor by: (i) the lessee; (ii) a party related to the lessee; or (iii) a third party unrelated to the lessor that is financially capable of discharging the obligations under the guarantee.
Proceeds from Issuance of ordinary shares and warrants, net of issuance costs.
The net cash inflow from the issuing of preference shares.
New CEO [Member]
New 2016 Convertible Loan [Member]
New US-based CFO [Member]
Non-executive director [Member]
Non Executive Directors [Member]
Non-refundable and non-creditable initial technology access fee payment.
Number of ordinary shares exchanged.
Number of ordinary shares that can be purchased through each tradeable warrant.
Number of preferred shares converted to ordinary shares following closing of IPO.
Number of preferred stock issued during the period.
Number of options exercised to ordinary shares.
Number of stock merged.
Number of warrants converted into additional warrants to purchase ordinary shares.
Options granted to consultant and services providers [Member]
Options granted to services providers [Member]
Oramed [Member]
Ordinary shares remain available for future grants.
Other current amount of restricted deposits.
Other issuance costs.
Percentage of aggregate purchase price paid in cash by purchasers equal to per month.
Percentage of cash fees of total proceeds.
Percentage of discount applicable to price per share.
Percentage to be paid for each payment received.
Percentage of number of shares issued to subscribers.
Percentage of per unit price.
Percentage of royalties to be paid.
Percentage of royalty payable on grants received by company.
Percentage of royalty payable on sales of products developed during commencing of seventh year.
Percentage of royalty payable on sales of products developed during first three years.
Percentage of royalty payable on sales of products developed during subsequent three years.
Percentage of warrants to purchase additional shares on conversion.
Placement Agency agreement with GP Numenkari Inc [Member]
Preferred Shares Series B- 1 [Member]
Preference Shares Series B [Member]
Price per share of preferred shares,
The value of non-current portion of non-current preferred shares.
Price per share.
The cash inflow from the exercise of options and warrants.
The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares, before issuance costs [member]]
The proportion of amount invested in a joint venture attributable to the entity.
The amounts payable resulting from provision for vacation related party transactions.
Public offering price per unit.
Reclassification from other reserves to additional paid in capital.
Reserved ordinary shares.
Right of use assets on obtained in exchange for new operating lease liabilities.
The noncurrent amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.
Risk free interest rate.
Dr. Graceau [Member]
Royalty amount payable.
Second amendment to Centillion preferred share purchase agreement [Member]
Series A preferred shares [Member]
Series B-1 preferred shares [Member]
Series B preferred shares [Member]
The non-current portion of severance pay obligations, net.
The amounts payable resulting from severance pay obligations related party transactions.
Share issue price per share.
Share-based Compensation Expense [member]
Shareholders exercised his right to acquire ordinary shares [Member]
Shares issued in conversion of debt.
Shares issued in conversion of debt, price per share.
Shares issued in conversion of debt, value.
Stock split.
Subscription agreements with select group of accredited investors for private placement [Member]
Transaction costs.
Under Company Plan [Member]
Underwriters fee.
Underwriters [Member]
Value of share options exercised in a share-based payment arrangement.
WFI [Member]
Warrant term.
Warrants converted into ordinary shares.
Warrants granted to purchase ordinary shares.
Warrants issued to purchase preferred shares.
Warrants issued to purchase shares.
Warrants issued to purchase shares after share split.
Warrants [Member]
The non-current portion of warrants to purchase ordinary shares.
Warrants to purchase preferred shares and shares [Member]
Warrants to purchase ordinary shares.
Warrants to series A preferred shares [Member]
Warrants to series B-1 preferred shares [Member]
Warrants to series B preferred shares [Member]
Warrants to purchase ordinary shares.
Percentage of weighted average cost of capital.
White Car [Member]
Issuance of shares due to the ATM program, net of issuance costs.
Number of Issuance of shares due to the ATM program, net of issuance costs.
Expiration of options and warrants.
Vested restricted share units.
Number of Vested restricted share units.
Right of use assets obtained in exchange for expanded period of operating lease liabilities.
ATM Program [Member]
The description of the entity's accounting policy for Recently Issued Accounting Pronouncements.
2012 Convertible Loan, 2016 Convertible Loan [Member]
Transfer from other reserves to additional paid in capital.
General and administrative expenses reversal.
Certain Service Provider [Member]
Certain Executive Officers [Member]
Former CEO [Member]
Investor Relations Services Agreement [Member]
Service monthly fees.
Restricted Share Units [Member]
The number of share options vested in a share-based payment arrangement.
Vest In Three Equal Installments [Member]
Amendment To Business Development Services Agreement [Member]
2012 Convertible Loan, preferred shares and warrants [Member]
Milestone payments.
Current assets
Non-current assets
Assets [Default Label]
Current liabilities
Non-current liabilities
Liabilities
Equity
Equity and liabilities
Profit (loss) from operating activities
IncomeFromChangeInFairValueOfFinancialLiabilitiesAtFairValueThroughProfitAndLoss
Other finance income (cost)
FinancialExpensesIncomeNet
Profit (loss) before tax
Adjusted weighted average number of ordinary shares outstanding
Cash flows from (used in) operating activities
Purchase of property, plant and equipment, classified as investing activities
Cash flows from (used in) investing activities
Payments of lease liabilities, classified as financing activities
Cash flows from (used in) financing activities
Adjustments to reconcile profit (loss)
Adjustments for increase (decrease) in trade accounts payable
Adjustments for increase (decrease) in other operating payables
AdjustmentsForChangesInWorkingCapital
Interest paid, classified as operating activities
Disclosure of income tax [text block]
Description of accounting policy for determining components of cash and cash equivalents [text block]
DescriptionOfAccountingPolicyForShortTermBankDepositsExplanatory
Description of accounting policy for restricted cash and cash equivalents [text block]
Description of accounting policy for property, plant and equipment [text block]
Description of accounting policy for intangible assets other than goodwill [text block]
Lease liabilities [Default Label]
Financial liabilities
Exercise price, share options granted
Number of share options expired in share-based payment arrangement
Number of share options exercisable in share-based payment arrangement
Weighted average exercise price of share options outstanding in share-based payment arrangement
Weighted average exercise price of share options exercisable in share-based payment arrangement
Intrinsic value of liabilities from share-based payment transactions for which counterparty's right to cash or other assets vested
Exercise price of outstanding share options
OtherCurrentRestrictedDeposits
Other current assets [Default Label]
Comprehensive income, attributable to non-controlling interests
Key management personnel compensation, share-based payment
Key management personnel compensation
ProvisionForVacationRelatedPartyTransactions
DirectorsFeeAndServicesRelatedPartyTransactions